A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Satyanarayana, T.
- Thermophiles–2013
Authors
1 Department of Microbiology, University of Delhi South Campus, New Delhi 110 021, IN
Source
Current Science, Vol 106, No 2 (2014), Pagination: 148-149Abstract
No Abstract.- Hepatoprotective Activity of Extracts from Stem of Mussaenda erythrophylla LAM. against Carbon Tetrachloride-Induecd Toxicity in Rats
Authors
Source
Asian Journal of Pharmaceutical Research and Health Care, Vol 2, No 1 (2010), Pagination: 23-31Abstract
Mussaenda erythrophylla (Rubiaceae) is native to western tropical Africa, occasionally seen in gardens and parks as ornamental plant in India. The Hepatoprotective activity of ethyl acetate and methanol extracts of M.erythrophylla (ME) Stem against carbon tetrachloride (CCl4) induced liver damage in Wistar albino rats. Ethyl acetate and methanolic extracts of ME (100,200mg/kg.p.o.), were administerd respectively, Silymarin (25 mg/kg.p.o.) was given as reference standard. The stem extracts were effective in protecting the liver against the injury induced by CCl4 in animals. This was evident from significant reduction in serum enzyme, SGOT, SGPT, ALP and Total bilirubin (TB).Various pathological changes like centribular necrosis and vacuolization were observed in CCL4 treated rats, which were significant protective activity in groups treated with ME and silymarin. It was concluded from the study that ethyl acetate and methanolic extracts of ME possess hepatoprotective activity against CCl4 induced hepatotoxicity in rats.
Keywords
Hepatoprotective, Carbon Tetrachloride, Mussaenda erythrophylla, Silymarin.- Hepatoprotective Activity of Capparis sepiaria Stem against Carbon Tetrachloride-Induced Hepatotoxicty in Rats
Authors
Source
Asian Journal of Pharmaceutical Research and Health Care, Vol 1, No 1 (2009), Pagination: 34-45Abstract
The hepatoprotective effect of the alcohol extract of Capparis sepiaria Linn. (Capparaceae) stem against carbon tetrachloride (CCl 4 )-induced toxicity was studied in albino rats. The rats were given daily pretreatment with alcohol extract of C. sepiaria (100 mg/kg) and the standard silymarin (25 mg/kg) orally for 7 days. The toxicant used on 7 th day was CCl 4 at a dose of 1.25 ml/kg as 1:1 mixture with olive oil. The extract produced significant (p<0.01) reduction in the elevated levels of aspartate transaminase (AST), alanine transaminase (ALT), total bilirubin (TB) and rise of decreased total protein level when compared with the toxic control.Keywords
Hepatoprotective, Capparis sepiaria , Carbon Tetrachloride, Silymarin.- The Estimation of Irinotecan HCl in Parenterals by RP-HPLC
Authors
1 Dept. of Pharma. Chem., Sree Chaitanya Institute of Pharmaceutical Sciences, LMD Colony, Karimnagar-505527, A.P., IN
2 Dept. of Pharma. Chem., Sultan-Ul-Uloom College of Pharmacy, Mount Pleasant, Road#3, Banjara Hills, Hyderabad-500034, IN
3 University College of Pharmaceutical Sciences, Andhra University, Visakhapatnam, A.P., IN
Source
Asian Journal of Research in Chemistry, Vol 2, No 1 (2009), Pagination: 54-56Abstract
A simple, precise, rapid and accurate reverse phase HPLC method developed for the estimation of Irinotecan HCl in tablet dosage form. A X-Terra RP C18, 250×4.6 mm i.d, 5 μm partical size, with mobile phase consisting of Methanol and 0.01 M Ammonium Acetate containing 0.1% formic acid and methanol in the ratio of 50:50 v/v was used. The flow rate was 1 ml/min and the effluents were monitored at 250 nm. The retention time was 4.69 min. The detector response was linear in the concentration of 120-360 mcg/ml. The respective linear regression equation being Y=166582.24x+86439.5. The limit of detection and limit of quantification was 0.06 and 0.18 mcg/ml respectively. The percentage assay of Irinotecan HCl was 99.09%. The method was validated by determining its accuracy, precision and system suitability. The results of the study showed that the proposed RP-HPLC method is simple, rapid, precise and accurate, which is useful for the routine determination of Irinotecan HCl in bulk drug and in its pharmaceutical dosage form.Keywords
Irinotecan HCl, RP-HPLC, Estimation, and Tablets.- The Estimation of Paclitaxel in Parenterals by RP-HPLC
Authors
1 Dept. of Pharma. Chem., Sree Chaitanya Institute of Pharmaceutical Sciences, LMD Colony, Karimnagar-505527, AP, IN
2 Dept. of Pharma. Chem., Sultan-Ul-Uloom College of Pharmacy, Mount Pleasant, Road 3, Banjara Hills, Hyderabad-500034, IN
3 University College of Pharmaceutical Sciences, Andhra University, Visakhapatnam, AP, IN
Source
Asian Journal of Research in Chemistry, Vol 2, No 1 (2009), Pagination: 90-92Abstract
A simple, precise, rapid and accurate reverse phase HPLC method developed for the estimation of Paclitaxel in Parenterals dosage form. A Unison US C18, 250×4.6 mm i.d, 5 μm partical size, with mobile phase consisting of Methanol and 0.02 M potassium dihydrogen phosphate in water (pH 2.5 adjusted with o-phosphoric acid) in the ratio of 80:20 v/v was used. The flow rate was 1 ml/min and the effluents were monitored at 225 nm. The retention time was 4.978 min. The detector response was linear in the concentration of 15-180 mcg/ml. The respective linear regression equation being Y=46411.83x+29.2578. The limit of detection and limit of quantification was 0.03 and 0.09 mcg/ml respectively. The percentage assay of Paclitaxel was 99.09%. The method was validated by determining its accuracy, precision and system suitability. The results of the study showed that the proposed RP-HPLC method is simple, rapid, precise and accurate, which is useful for the routine determination of Paclitaxel in bulk drug and in its pharmaceutical dosage form.Keywords
Paclitaxel, RP-HPLC, Estimation, and Parenteral.- Formulation and Characterization of Tramadol Emulgel
Authors
1 Department of Pharmaceutics, Mother Teresa Pharmacy College, Sathupally-507303, Khammam Dist, IN
Source
Research Journal of Topical and Cosmetic Sciences, Vol 8, No 2 (2017), Pagination: 53-60Abstract
Topical drug delivery system (TDDS) facilitates the passage of therapeutic quantities of drug substance through the skin and into the general circulation for their systemic effects. Although having plenty of advantages over other routes of administration topical drug delivery system is having certain limitations including hydrophilic drugs cannot easily penetrate across skin, to overcome this problem drug made into sufficient lipophilic or lipophilic drugs are sued along with certain penetration enhancers which help to achieve desired results. Tramadol is a narcotic analgesic proposed for moderate to severe pain. It may be habituating. Tramadol and its metabolites are excreted primarily in the urine with observed plasma half-lives of 6.3 and 7.4 hours for tramadol and M1, respectively. Approximately 30% of the dose is excreted in the urine as unchanged drug, whereas 60% of the dose is excreted as metabolites. On this contest, emulgel was formulated using carbopol 934 and HPMC K15M, liquid paraffin as oil phase, emulsifying agents like tween 20 and span 20 and propylene glycol as permeation enhancers. On basis of quality of emulgel produces total eight formulations F1 to F8 were selected. They were evaluated for physical appearance, pH, rheological study, drug content and in-vitro drug permeation study, FTIR and globule size determination. The skin irritation test was performed on rabbit’s skin using best formulation F7. Thus, the formulated emulgel had a distinct advantage over existing conventional dosage form in that the drug permeation was found to be rapid across the skin and hence the increased therapeutic response by bypassing 1st pass metabolism and with no gastro intestinal bleeding and also patient compliance.Keywords
Emulsion, Gel, Transdemal Drug Delivery Systems, Tramadol, In-Vitro Drug Permeation Study.References
- Vikas Singla, Seema Saini, Baibhav Joshi, And A.C Rana. Emugel: A New platform for topical drug delivery. Int J Pharm and Bio Sci 2012; 3(1):485-98.
- Piyusha Deveda, Anukur Jain, Naveen Vyas, Hemant Khambete And Sanjay Jain. Gellified emulsion for sustained delivery of itraconzole for topical fungal diseases. Int J Pharm pharmaceut sci 2010; 2(1):104-12.
- Canan Hascisek, Aysel Bediz-Olcer, Nursin Gonul. Preparation and evaluation of different gel formulations for transdermal delivery of meloxicam. Int J Pharm 2009; 2(1): 177-85.
- Rachit Khullar, Saini S, Seth N, Rana AC. Emulgels: A surrogate approach for topically used hydrophobic drugs. Int J Pharm Bio Sci 2011; 1(3):117-28.
- Magdy I. Mohamed. Optimization of chlorphenesin emulgel formulation. The AAPS journal 2004; 6 (3); 1-7.
- Anukur Jain, Piyusha Deveda, Naveen Vyas, Jitendra Chauhan, Hemant Khambete , Sanjay Jain. Development of antifungal based gel for topical fungal infections. Int J Pharm Res Dev 2011; 2 (12):18-25.
- Rachit Khullar, Deepindar Kumar, Nimrata Seth, Seema Saini. Formulation and evaluation of mefenamic acid emulgel for topical drug delivery. Saudi pharm J 2011; (20):63-67.
- Dignesh M. Khunt, Ashish D. Mishra, Dinesh R. Shah. Formulation design and development of piroxicam emulgel. Int J Pharm Tech Res 2012; 4 (3):1332-44.
- Ashish Y. Pawar et al. Formulation, Development and Evaluation of Topical Microemulsion Gels for Nimsulide. J Pharm Res 2011; 4(4):1004-1006.
- Sushil Raut,Vaibhav Uplanchiwar, Santosh Bhadoria Avinash Gahane, Sunil Kumar Jain, Shrishail Patil. Comparitive evaluation of zidovudine Loaded hydrogels and emulgels. Res J Pharm Tech 2012; 5(1):41-5.
- Singla Vikas, Saini Seema, Rana AC, Singh Gurpreet. Development and evaluation of topical emulgel of lornoxicam using different polymer bases. Int Pharm Sci 2012; 2(3):36-44.
- Joshi Baibhav, Singh Gurpreet, Rana AC, Saini Seema. Development and characterization of clarithromycin emulgel for topical delivery. Int J Drug Dev Res 2012; 4(3):310-23.
- Sonal V. Ghodekar, Shilpa P. Chaudhari, Mukesh. P. Ratnaparakhi. Development and characterization of silver sulfadiazine emulgel for topical drug delivery. Int J Pharm Pharmaceut Sci 2012; 4(4):305-16.
- Arunachalam A et al. Transdermal drug delivery systems: A review. Current Pharma Res 2010; 1(1): 70-81.
- Meera C Singh, Ajinkya S Naik, Sawant SD. Transdermal drug delivery system with major emphasis on transdermal patches. J Pharm Res 2010; 3(10): 2537-2543.
- Robinson JR, Lee VH. Controlled drug delivery fundamentals and applications. 2nd ed. New Delhi: CBS Publishers and Distributors; 2005; vol 29: 523-55.
- KottaKranthi Kumar, Sasikanth K, Sabareesh M, Dorababu N. Formulation and evaluation of diacerein cream. Asian J Pharm Clinical Res 2011; 4(2): 93-98.
- Jonathan Hadgraft, Richard H Guy. Transdermal drug delivery: development issues and research initiative. Marcel Dekker. Vol 35: 1-16.
- Divyesh Patel, Nirav Patel, MeghalParmar, NavpreetKaur. Transdermal drug delivery system: review. Int J BiopharmToxicol Res 2011; 1(1): 61-80.
- VirendraYadav. Transdermal drug delivery system: review. Int J Pharm Sci Res2012; 3(2): 376-382.
- Ankush I Shembale, Dipak K Borole, Rajesh T Lohiya. Useful permeation enhancers for transdermal drug delivery: A review. Int J Pharma Res Dev 2010; 2(5):1-6.
- Loyd VA, Nicholas GP, Ansel HC. Pharmaceutical dosage forms and drug delivery systems. 8th ed. Philadelphia: Lippincott Williams and Wilkins 2005; 298-315.
- Bhavsar JD, Brahambhatt VG, Patel MR, Patel KR, Patel NM. Review article: Novel approaches in semisolids. Int J Pharm World Res 2011; 2(1): 1-22.
- Patil Bharat, MandoreParesh, Sharma RK, Tekade BW, Thakre VM, Patil VR. A review: novel advances in semisolid dosage form and patented technology in semisolid dosage forms. Int J Pharm Tech Res 2011; 3(1): 420-430.
- Rachit Khullar, Saini S, Seth N, Rana AC. Emulgels: a surrogate approach for topically used hydrophobic drugs. Int J Pharm Bio Sci 2011; 1(3): 117-128.
- Joshi Baibhav, Singh Gurupreet, Rana AC, SainiSeema, Single Vikas. Emulgel: a comprehensive review on the recent advances in topical drug delivery. Int Res J Pharm 2011; 2(11): 66-70.
- Binda Nair et al. A review on topical diclofenac or in musculoskeletal diseases. Pharmaceuticals 2010; 3: 1892-1908.
- Peter Guni et al. Osteoarthritis rational approach to treating individual. Best Practice Res Clin Rheumatology 2006; 20(4): 721-740.
- Formulation and Characterization of Tramadol HCl Transdermal Patch
Authors
1 Department of Pharmaceutics, Mother Teresa Pharmacy College, Sathupally, Khammam Dist., 507303, IN
Source
Asian Journal of Pharmacy and Technology, Vol 8, No 1 (2018), Pagination: 23-28Abstract
Transdermal drug delivery leads direct access to the systemic circulation through the skin which bypasses drugs from the hepatic first pass metabolism leading to increase bioavailability. Tramadol HCl has been selected as model drug because it has low bioavailability. It exhibit all physicochemical characteristics required for the transdermal patch. Transdermal patches of Tramadol HCl were prepared by solvent casting method using different polymers i.e. HPMCK4M, HPMCK15M, HPMCE5.Propyleneglycol was used as plasticizer and methanol was used to dissolve the drug. Water was used as solvent to dissolve the polymer. The prepared formulations were evaluated for drug content uniformity, in vitro diffusion study, thickness, tensile strength, moisture content, folding endurances etc. Amongst all formulation, formulation F3 had more desirable characteristic and shows 88.36% drug release in 12hr. Release kinetic can be described by Higuchi model with anomalous diffusion as a release mechanism. The Transdermal patch formulated from HPMCK4M, HPMCK15M and HPMCE5 showed satisfactory physicochemical properties. The ratios of hydrophilic polymers HPMCK4M, HPMCK15M and HPMCE5 good moisture content property, good tensile strength, folding endurances and in-vitro drug release. So, it can be concluded that such a matrix type patches of HPMCK4M, HPMC K15M and HPMCE5 could be a good carrier in transdermal delivery of Tramadol HCl. FTIR studies showed there were no incompatibilities between drug and other excipientsKeywords
Transdermal Patch, Tramadol HCl, HPMC.References
- Kandavilli S, Nair V, Panchagnula R. Polymers in transdermal drug delivery systems, Pharmaceutical Technology 2002, 62-78. Available from: http://www.pharmtech.com/.
- Guy RH. Current status and future prospects of transdermal drug delivery, Pharm Res 1996, 13, 1765-1769.
- Guy RH, Hadgraft J, Bucks DA. Transdermal drug delivery and cutaneous metabolism, Xenobiotica 1987, 7, 325-343.
- Chein YW. Transdermal Controlled Systemic Medication. New York and Basel, Marcel Dekker Inc. 1987; 159-176.
- Comfort AR, Sherchuk I, Ohe JH, Dinh SM. in-vitro characterization of a solvent controlled nitroglycerine transdermal system. J Controlled Rel 1995; 34, 193-201.
- Carpel MC, Erasmo AME, Rawena SW, Elizebath PH, Rondoll Z. Drug Intelligence Clinical Pharmacy; 1987.
- Chien Yie W. Transdermal drug delivery and delivery systems. 2nd Ed. New York: Marcel Dekkar Inc; 1992.
- Obsorne, Hattzenbuler. The influence of skin surface lipids on topical formulations. New York: Marcel Dekker Inc; 1990.
- Marjukka ST, Bouwsira JA, Urtti A. Chemical enhancement of percutaneous absorption in relation to stratum corneum structural alterations. J Control Rel 1999; 59:149-61.
- Prausnitz MR, Mitragotri S, Langer R. Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov 2004; 3(2):115-24.
- Chatterjee CC. Human physiology. Medical allied agency. Vol II. Calcutta India: p1:p68-80.
- Guy RH. Current status and future prospects of transdermal drug delivery. Pharm Res 1996;13(12):1765-69.
- Hadgraft J. Recent developments in topical and transdermal delivery. Eur J Drug Metab Pharmacokinetic 1996; 21:165-73.
- Hadgraft J. Passive enhancement strategies in topical and transdermal drug delivery. Int J Pharm 1999; 184:1-6.
- Kydoneius AF. Fundamentals of transdermal drug delivery, CRC Press, Boca Raton Florida; 1987:3.
- Franz TJ, Tojo K, Shah KR, Kydonieus AF. Treatise on controlled drug delivery, Marcel Dekker, New York; 341-421.
- Vecchia BE, Bunge AL. Transdermal drug delivery, 2nd edition, Marcel Dekker, New York; 25-55.
- Shirley MN. Compatibility and synergy of permeation enhancers with solvents, excipients and drugs in Drug Permeation Enhancement, Hsieh DS, Ed., Marcel Dekker, New York 1994;91106.
- Barry BW. Editor Dermatological formulations, Percutaneous Absorption, Marcel Dekker, New York 1983; 127-233.
- Pongjanyakul T, Prakongpan S, Priprem A. Acrylic matrix type nicotine transdermal patches: in-vitro evaluation and batch-tobatch uniformity. Drug Dev Ind Pharm 2003; 29(8):843-53.
- Shin SC, Shin EY, Cho CW. Enhancing effects of fatty acid on piroxicam permeation through rat skins. Drug Dev Ind Pharm 2000; 26(5):563-6.
- Tipre DN, Vavia PR. Formulation, optimization and stability study of transdermal therapeutic system of nicorandil. Pharm Dev Technol 2002; 7(3):325-32.
- Verma PRP, Iyer SS. Controlled transdermal delivery of propranolol using HPMC matrices: Design and in-vitro and invivo evaluation. J Pharm Pharmacol 2000; 52:151-6.
- Adrian PF, Schiller R, Motzkers HW, Gunther C, Muller RH, Rolph L. Transdermal delivery of highly lipophilic drugs: in-vitro fluxes of antiestrogens, permeation enhancers and solvent from liquid formulations. Pharm Res 2002; 19(5):661-8.
- Cross SE, Roberts MS. Physical enhancement of transdermal drug application: Is delivery technology keeping up with pharmaceutical development. Curr Drug Deliv 2004; 1:81-92.
- Aqil M, Sultana Y, Ali A, Dubey K, Najmi AK, Pillai KK. Transdermal drug delivery systems of a beta-blocker-Design, invitro and in-vivo characterization. Drug Deliv 2004; 1(1):27-31.
- Vyas SP, Singh R, Asati RK. Liposomally encapsulated diclofenac for sonophoresis induced systemic delivery. J Microenapsul 1995; 12(2):149-154.